Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years]. [Article in Japanese] Hironishi M, Ishimoto S, Sawanishi T, Miwa H, Kawachi I, Kondo T. Source Department of Internal Medicine, Seishokai Kasei-Tamura Hospital.
Contributing Author: Gina Flores on June 13, 2012 Caregiver Story Spotlight | Shield HealthCare “What Makes Caregiving Rewarding?” Story Contest Story by Arthur B. My name is Arthur and I am a single father of three kids.
Multiple sclerosis: pathology and pathogenesis Monday, May 30, 2011, 17:15 – 18:15 The pathology of fulminant neuromyelitis optica with extremely high level of serum anti aquaporin 4 antibody K. Maruyama, M.
Purpose: To prospectively assess sensitivity and specificity of diffusion indexes of the corpus callosum (CC) for differentiating relapsing neuromyelitis optica (RNMO) from relapsing-remitting multiple sclerosis (RRMS), by using final clinical diagnosis as the reference standard. Materials and Methods: Participants provided informed consent; the study was approved by the institutional review board. Forty-six consecutive patients with RRMS (18 men, 28 women; mean age, 37.7 years; range, 18–58 years) and 26 consecutive patients with RNMO (two men, 24 women; mean age, 38.6 years; range, 19–59 years) underwent diffusion-tensor magnetic resonance imaging.
Background: Neuromyelitis optica (NMO) is a CNS demyelinating disease characterized by relatively selective injury to the optic nerves and spinal cord. As the prognosis and treatment differ between NMO and multiple sclerosis (MS), distinguishing these two diseases in patients presenting optic neuritis (ON) is important
Backgrounds: The distinction between neuromyelitis optica (NMO) and multiple sclerosis (MS) has long been a debate in Asia. The most specific finding for NMO is a longitudinally extensive, central cord lesion on MRI in the setting of myelitis (LETM), which is very rare in MS. The MRI criterion for LETM (contiguous spinal cord lesion 3 or more segments in length) is crucial.
Background: Neuromyelitis optica (NMO) is a rare inflammatory disease. Average age at onset is 35 years. Few data exist on patients with pediatric-onset NMO (p-NMO), with disease onset before age 18 years.
OBJECTIVE: To analyze treatment response in Brazilian patients with neuromyelitis optica. DESIGN: Retrospective review. SETTING: Neuroimmunology Clinic of the Federal University of Sao Paulo, Sao Paulo, Brazil